Abstracts tagged "interstitial lung disease"

Abstract Number: 0804 • ACR Convergence 2024
Serologic and Clinical Predictors of Progressive Pulmonary Fibrosis in Rheumatoid Arthritis-associated Interstitial Lung Disease Progression: A Prospective Longitudinal Cohort
Sung Hae Chang¹, Misti Paudel², Gregory McDermott³, Qianru Zhang⁴, You-Jung Ha⁵, Jeong Seok Lee⁶, Min Uk Kim⁷, Chan Ho Park⁸, Ji-Won Kim⁹, Jang Woo Ha¹⁰, Sang Wan Chung¹¹, Sung Won Lee¹², Eun Ha Kang⁵, Yeon-Ah Lee¹³, Jung-Yoon Choe¹⁴, Yong-Beom Park¹⁵, Eun Young Lee¹⁶ and Jeffrey Sparks¹⁷, and the KOrean Rheumatoid Arthritis Interstitial Lung Disease (KORAIL) group, ¹Brigham and Women's Hospital/Soonchunhyang University, College of Medicine, Boston, MA, ²Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ³Brigham and Women's Hospital, Brookline, MA, ⁴Harvard medical school, Cambridge, MA, ⁵Seoul National University Bundang Hospital, Seongnam, South Korea, ⁶Korea Advanced Institute of Science and Technology, KAIST,, Daejeon, Republic of Korea, ⁷SMG-SNU Boramae Medical Center, Seoul, Republic of Korea, ⁸Soonchunhyang University College of Medicine,, Cheonan-si, Republic of Korea, ⁹Daegu Catholic University School of Medicine, Nam-gu, Daegu, South Korea, ¹⁰Yonsei university college of medicine, Seodaemun-gu, Seoul, South Korea, ¹¹Kyung Hee University Hospital, Seoul, Republic of Korea, ¹²Soonchunhyang University Cheonan Hospital, Seoul, South Korea, ¹³Kyung Hee University Hospital, Seoul, South Korea, ¹⁴Catholic University of Daegu School of Medicine, Daegu, Republic of Korea, ¹⁵Yonsei University College of Medicine, Seoul, Republic of Korea, ¹⁶3Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea, ¹⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: Predictors of progressive pulmonary fibrosis (PPF) in patients with rheumatoid arthritis-associated interstitial lung disease (ILD) are unclear but may be due to inflammation or…
Abstract Number: 1112 • ACR Convergence 2024
Pleuroparenchymal Fibroelastosis Associated with Connective Tissue Diseases (PPFE-CTD)
Maximiliano Diaz Menindez¹, Alejandro Diaz Arumir Vergara², Vivian Shing², carolyn mead harvey³, Ana Zamora Martinez² and Vivek Nagaraja⁴, ¹Mayo Clinic School of Graduate Medical Education, Phoenix, AZ, ²Mayo Clinic, Phoenix, ³Mayo Clinic Florida, Jacksonville, FL, ⁴Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Pleuroparenchymal Fibroelastosis (PPFE) is a rare idiopathic interstitial pneumonia characterized by fibrosis of the visceral pleura and subpleural parenchyma, predominantly affecting the upper lobes.…
Abstract Number: 1585 • ACR Convergence 2024
Characterization of the Fecal Metabolome in Early Systemic Sclerosis
Arissa Young¹, Kristofer Andreasson², Jen Labus³, Nedas Matulianos⁴, Blake Wilde¹, Jonathan Jacobs³, Heather Christofk⁴ and Elizabeth Volkmann⁵, ¹UCLA, Los Angeles, CA, ²Lund University, Lund, Sweden, ³UCLA, Los Angeles, ⁴University of California Los Angeles, Los Angeles, CA, ⁵University of California, Department of Medicine, Los Angeles, CA, USA, Los Angeles
Background/Purpose: Previous studies have shown that alterations in gut microbiota are present early in systemic sclerosis (SSc) (Andréasson et al. 2022) and are associated with…
Abstract Number: 1955 • ACR Convergence 2024
Ultrasound for Screening of Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Review and Meta Analysis
Ikwinder Preet Kaur¹, Karishma Ramsubeik², Thway Myant³, Luis Sanchez-Ramos⁴, Laurie Ramrattan⁵ and Gurjit Kaeley⁶, ¹University of Florida College of Medicine, Jacksonville, FL, ²Baptist Health, Jax, FL, ³UF Jacksonville, Mia, FL, ⁴University of Florida college of Medicine, Jacksonville, ⁵University of Florida, Jacksonville, FL, ⁶UF COM-J, Ponte Vedra Beach, FL
Background/Purpose: Clinically significant Interstitial Lung Disease (ILD) can occur in up to 10 percent of Rheumatoid Arthritis (RA) patients, which is associated with considerable morbidity…
Abstract Number: 2305 • ACR Convergence 2024
Anti-Ku Positivity in Primary Sjögren’s Disease Is Associated with a More Systemic Active Disease
Marie ROBERT¹, Yann Nguyen², Yurdagül Uzunhan³, Benjamin Terrier⁴, Yves Allenbach⁵, Alain Meyer⁶, Jacques-Eric Gottenberg⁷, JEROME HADJADJ⁸, Zahir Amoura⁹, ARNAUD HOT¹⁰, Eléonore Bettacchioli¹¹, Elisabeth Aslangul¹², Rakiba Belkhir¹³, Frederic Desmoulins¹⁴, Elisabeth Bergé¹⁴, Pascale Chrétien¹⁵, Pascale Roland-Nicaise¹⁶, Claire Goulvestre¹⁷, Jean-Luc Charuel¹⁸, Benoit Nespola¹⁹, Nicole Fabien²⁰, Eric Ballot²¹, Gaetane Nocturne¹⁴, Xavier Mariette¹⁴, Samuel Bitoun¹ and Raphaele Seror²², ¹Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicetre, France, ²Université Paris Saclay, Clichy, Ile-de-France, France, ³Service de Pneumologie, Hôpital Avicenne, AP-HP, Bobigny, France, ⁴Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, ⁵Service de Médecine interne et immunologie clinique, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France, ⁶UR3072, Physiology Department, Rheumatology Department, University Hospital of Strasbourg, Strasbourg, France, ⁷Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ⁸Service de Médecine interne, Hôpital Saint-Antoine, AP-HP, Paris, Ile-de-France, France, ⁹French National Reference Centre for Systemic Lupus Erythematosus, Pitié-Salpêtrière Hospital, Paris, France, ¹⁰Service de Médecine interne, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France, ¹¹Service de Rhumatologie, CHU de Brest, Brest, France, ¹²Service de Médecine interne, Hôpital Louis Mourier, AP-HP, Colombes, France, ¹³Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre, France, ¹⁴Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, ¹⁵Laboratoire d'immunologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, France, ¹⁶Laboratoire d'immunologie, Hôpital Bichat, AP-HP, Paris, France, ¹⁷Laboratoire d'immunologie, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, ¹⁸Laboratoire d'immunologie, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France, ¹⁹Laboratoire d’immunologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ²⁰Laboratoire d'immunologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France, ²¹Laboratoire d'immunologie, Hôpital Saint-Antoine, AP-HP, Paris, Ile-de-France, France, ²²Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France
Background/Purpose: Sjögren’s disease (SjD) is an autoimmune disease characterized by a wide range of symptoms, and 30% to 60% of patients developed systemic manifestations. The…
Abstract Number: 2687 • ACR Convergence 2024
Therapeutic Choices in Systemic Sclerosis Associated Interstitial Lung Disease, a Survey of International Experts
Michael Macklin¹, Iazsmin Bauer Ventura¹ and Dinesh Khanna², ¹University of Chicago, Chicago, IL, ²University of Michigan, Ann Arbor, MI
Background/Purpose: The therapeutic options for systemic sclerosis-associated interstitial lung disease (SSc-ILD) have evolved rapidly, with recent guidelines released by the ACR and American Thoracic Society…
Abstract Number: 0299 • ACR Convergence 2024
Real-World Tolerability of Nintedanib in Connective Tissue Disease-Associated Interstitial Lung Disease
Saloni Goyal, Briana DiSilvio and Joanna Marco, Allegheny Health Network, Pittsburgh, PA
Background/Purpose: Nintedanib is an antifibrotic medication used to treat interstitial lung disease (ILD), including connective tissue disease-associated ILD (CTD-ILD). Clinical trials that led to its…
Abstract Number: 0642 • ACR Convergence 2024
Anti-Myxovirus Resistance Protein 1: A Novel Biomarker for Autoimmune Myositis and Interstitial Lung Disease in Systemic Lupus Erythematosus
Eugene Krustev¹, Marvin Fritzler², Sasha Bernatsky³, Yvan St-Pierre⁴, Evelyne Vinet⁵, Christian Pineau⁶, Arielle Mendel⁷, Faras Kalache⁸, Louis-Pierre Grenier⁸, Thaisa Cotton⁸, Omid Zahedi⁹ and May Choi¹, ¹University of Calgary, Calgary, AB, Canada, ²Mitogen Diagnostics Corp, Calgary, AB, Canada, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University Health Center, Montreal, QC, Canada, ⁵McGill University Health Centre, Montreal, QC, Canada, ⁶McGill University, Montreal, QC, Canada, ⁷Division of Rheumatology, Department of Medicine, McGill University and Centre for Outcomes Research and Evaluation, McGill University Health Centre, Montreal, QC, Canada, ⁸Division of Rheumatology, Department of Medicine, McGill University, Montreal, QC, Canada, ⁹Division of Rheumatology, Department of Medicine, University of Alberta Hospital, Edmonton, AB, Canada
Background/Purpose: Although autoimmune myositis (AIM) and interstitial lung disease (ILD) are uncommon in systemic lupus erythematosus (SLE), they are associated with worse outcomes. Myxovirus Resistance…
Abstract Number: 0830 • ACR Convergence 2024
Activation of Autoreactive Lymphocytes in the Lung by STING Gain-of-function Mutation Expressing Radioresistant Cells
Kevin Gao¹, Kristy Chiang¹, Sharon Subramanian¹, Xihui Yin², Paul Utz³, Kerstin Nundel¹, Katherine A. Fitzgerald⁴ and Ann Marshak-Rothstein¹, ¹UMass Chan Medical School, Worcester, MA, ²Stanford University School of Medicine, Palo Alto, CA, ³Stanford University, Stanford, CA, ⁴UMass Chan Medical School, Worchester, MA
Background/Purpose: Gain-of-function mutations in STING, a critical mediator of dsDNA sensing, lead to a severe autoinflammatory syndrome known as STING-Associated Vasculopathy with onset in Infancy…
Abstract Number: 1142 • ACR Convergence 2024
Disease Trajectory in anti-MDA5 Dermatomyositis Patients Presented with Different Stage of Interstitial Lung Disease
TING-YUAN LAN¹, Tai-Ju Lee², Ting-Wei Chang³, Chiao-Feng Cheng⁴, Chieh-Yu Shen⁵, Cheng-Hsun Lu⁶, Kuan-Yen Lin⁷, Song-Chou Hsieh⁸ and Ko-Jen Li⁹, ¹National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan, ²National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan (Republic of China), ³National Taiwan University Hospital HsinChu Branch, Taichung, Taiwan, ⁴National Taiwan University Hospital Yun-Lin Branch, Yun-Lin County, Taiwan, ⁵National Taiwan Universtiy Hospital, Taipei, Taiwan (Republic of China), ⁶National Taiwan University Hospital, Taipei, Taiwan, ⁷National Taiwan University Hospital Hsin-Chu branch, Hsinchu, Taiwan (Republic of China), ⁸National Taiwan Unuversity Hospital, Taipei City, Taiwan, ⁹National Taiwan University Hospital, Taipei
Background/Purpose: The necessity of intensive combination immunotherapy for all patients with anti-MDA5 ILD is debated, given the variable progression of the disease, risk of infection…
Abstract Number: 1588 • ACR Convergence 2024
Validation of a Lung Ultrasound Interpretation Criteria for Interstitial Lung Disease Screening in Systemic Sclerosis and Inflammatory Myopathy
Robert Fairchild¹, Diane Mar², Mariani Deluna³, Henry Guo³, David Fiorentino⁴ and Lorinda Chung⁵, ¹Stanford University, San Francisco, CA, ²VA Palo Alto / Stanford, Palo Alto, CA, ³Stanford University, Palo Alto, CA, ⁴Stanford University, Menlo Park, CA, ⁵Stanford University, Woodside, CA
Background/Purpose: Interstitial lung disease (ILD) is a common complication of connective tissue disease (CTD) with a high prevalence in SSc and inflammatory myopathy (IM). Early…
Abstract Number: 1965 • ACR Convergence 2024
Artificial Intelligence Assisted Interpretation of Lung Ultrasound Imaging for the Detection of Interstitial Lung Disease
Robert Fairchild¹, Diane Mar², Mariani Deluna³, Matthew Baker⁴, suzanne Tamang⁵, Henry Guo³, David Fiorentino⁴ and Lorinda Chung⁶, ¹Stanford University, San Francisco, CA, ²VA Palo Alto / Stanford, Palo Alto, CA, ³Stanford University, Palo Alto, CA, ⁴Stanford University, Menlo Park, CA, ⁵Stanford University, Atherton, CA, ⁶Stanford University, Woodside, CA
Background/Purpose: Interstitial lung disease (ILD) is a serious complication of SSc and inflammatory myopathy (IM), necessitating accurate and early detection for improved outcomes. Lung ultrasound…
Abstract Number: 2310 • ACR Convergence 2024
Prospective Evaluation of Pulmonary Involvement in Patients with Primary Sjögren’s Disease, Using Pulmonary Function Tests and High Resolution Computed Tomography, Reveals High Prevalence of Subclinical Interstitial Lung Disease, Along with Small Airways Disease
Panagiotis Panagopoulos¹, Loukas chatzis², Eirini Chatzinikita³, Katerina Malagari⁴, Theodoros Vassilakopoulos³, Athanasios Tzioufas⁵ and Andreas Goules⁶, ¹Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ²Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Cholargos Athens, Greece, ³Department of Physiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ⁴2nd Department of Radiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ⁵LAIKO HOSPITAL, Athens, Greece, ⁶GENERAL HOSPITAL LAIKO ATHENS, Athens, Greece
Background/Purpose: Interstitial lung disease (ILD) and small airways disease (SAD) are frequent pulmonary manifestations of primary Sjögren’s disease (SjD). The relation between these two entities…
Abstract Number: PP07 • ACR Convergence 2024
My Journey with Diffuse Scleroderma and Interstitial Lung Disease: A Pharmacist’s Perspective
Joseph Washington, Cencora, Washington, DC
Background/Purpose: Since my diagnosis with diffuse scleroderma and ILD, I have balanced the roles of patient and young pharmacist. A duality that has surely impacted…
Abstract Number: 0093 • ACR Convergence 2023
Single Cell RNA-seq and Mass Cytometry Reveal a Cytotoxic CD8 Effector T Cell Population Associated with Interstitial Lung Disease in Systemic Sclerosis Patients
Ye Cao¹, Takanori Sasaki², Richard Ainsworth³, Kim Taylor⁴, Nunzio Bottini⁵, Mehreen Elahee⁶, Edy Kim⁷, Francesco Boin³ and Deepak Rao⁷, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴University of California San Francisco, San Francisco, CA, ⁵University of California, San Francisco, CA, ⁶University of Pittsburgh Medical Center, Pittsburgh, PA, ⁷Brigham and Women's Hospital, Boston, MA
Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and mortality in systemic sclerosis (SSc). We aimed to identify features of circulating immune…

« Previous Page
1
…
6
7
8
9
10
…
39
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].